Knowthestock.com
ALLO - Allogene Therapeutics Inc
We couldn't determine Recommendation based on the data we have.




Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Allogene Therapeutics Inc (ALLO) - www.allogene.com
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Exchange - NASDAQ
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO -
Employees - 265
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.